References

• 2004Prevalence, Severity, and Unmet Need for Treatment of Mental Disorders in the World Health Organization World Mental Health Surveys3,448 cited
• 2005Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies1,502 cited
• 2005Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology616 cited
• 2005Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review387 cited
• 2004Comorbidity of Anxiety and Depressive Disorders: Issues in Conceptualization, Assessment, and Treatment235 cited
• 2004Escitalopram in the treatment of generalized anxiety disorder: Double-blind, placebo controlled, flexible-dose study175 cited
• 2004Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, fixed-dose study164 cited
• 2003Escitalopram in the Treatment of Panic Disorder139 cited
• 2005Escitalopram in the treatment of social anxiety disorder126 cited
• 2005A 24-Week Randomized, Double-Blind, Placebo-Controlled Study of Escitalopram for the Prevention of Generalized Social Anxiety Disorder116 cited
• 2005Treatment of generalized anxiety disorder with escitalopram: Pooled results from double-blind, placebo-controlled trials116 cited
• 2006Escitalopram and paroxetine in the treatment of generalised anxiety disorder